Skip Navigation

Cardiovascular Research 2003 60(2):217-219; doi:10.1016/j.cardiores.2003.09.006
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haramaki, N.
Right arrow Articles by Ikeda, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haramaki, N.
Right arrow Articles by Ikeda, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Statins for heart failure: a potential for new treatment

Nobuya Haramaki* and Hisao Ikeda

Department of Internal Medicine III, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan

*Corresponding author. Tel.: +81-942-35-3311; fax: +81-942-33-6509. Email address: haramaki@med.kurume-u.ac.jp

Received 1 September 2003;
The first 10% of the full text of this article appears below.

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, statins, are potent and widely used cholesterol-lowering drugs. Since the pathophysiology of atherosclerosis involves the uptake of modified low density lipoprotein (LDL) cholesterol, it has been generally assumed that the cholesterol-lowering effect of statins mediates the beneficial effects on atherosclerotic disease. Several clinical trials have demonstrated beneficial effects of statins in the primary and secondary prevention of coronary heart disease. However, subgroup analysis and meta-analysis of cholesterol-lowering trials indicated that the risk of atherosclerotic disease in patients treated with statins is significantly lower than the expected risk based on the level of serum cholesterol. These findings mostly suggest the existence of statins' beneficial effects beyond their cholesterol-lowering effects, which are termed "pleiotropic effects". The pleiotropic effects of statins involved improvement of endothelial function, stabilization . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
I. H. Zucker
Novel Mechanisms of Sympathetic Regulation in Chronic Heart Failure
Hypertension, December 1, 2006; 48(6): 1005 - 1011.
[Full Text] [PDF]